Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Murali, R; Wiesner, T; Scolyer, RA.
Tumours associated with BAP1 mutations.
Pathology. 2013; 45(2):116-126
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Wiesner Thomas
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
BAP1 (BRCA1-Associated Protein 1) was initially identified as a protein that binds to BRCA1. BAP1 is a tumour suppressor that is believed to mediate its effects through chromatin modulation, transcriptional regulation, and possibly via the ubiquitin-proteasome system and the DNA damage response pathway. Germline mutations of BAP1 confer increased susceptibility for the development of several tumours, including uveal melanoma, epithelioid atypical Spitz tumours, cutaneous melanoma, and mesothelioma. However, the complete tumour spectrum associated with germline BAP1 mutations is not yet known. Somatic BAP1 mutations are seen in cutaneous melanocytic tumours (epithelioid atypical Spitz tumours and melanoma), uveal melanoma, mesothelioma, clear cell renal cell carcinoma, and other tumours. Here, we review the current state of knowledge about the functional roles of BAP1, and summarise data on tumours associated with BAP1 mutations. Awareness of these tumours will help pathologists and clinicians to identify patients with a high likelihood of harbouring germline or somatic BAP1 mutations. We recommend that pathologists consider testing for BAP1 mutations in epithelioid atypical Spitz tumours and uveal melanomas, or when other BAP1-associated tumours occur in individual patients. Tumour tissues may be screened for BAP1 mutations/loss/inactivation by immunohistochemistry (IHC) (demonstrated by loss of nuclear staining in tumour cells). Confirmatory sequencing may be considered in tumours that exhibit BAP1 loss by IHC and in those with equivocal IHC results. If a BAP1 mutation is confirmed in a tumour, the patient's treating physician should be informed of the possibility of a BAP1 germline mutation, so they can consider whether genetic counselling and further testing of the patient and investigation of their family is appropriate. Recognition and evaluation of larger numbers of BAP1-associated tumours will also be necessary to facilitate identification of additional distinct clinico-pathological characteristics or other genotype-phenotype correlations that may have prognostic and management implications.
Find related publications in this database (using NLM MeSH Indexing)
Adenocarcinoma - diagnosis Adenocarcinoma - genetics Adenocarcinoma - metabolism
Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism
Carcinoma, Neuroendocrine - diagnosis Carcinoma, Neuroendocrine - genetics Carcinoma, Neuroendocrine - metabolism
DNA Mutational Analysis -
Gene Deletion -
Genetic Predisposition to Disease -
Humans -
Immunohistochemistry - methods
Lung Neoplasms - diagnosis Lung Neoplasms - genetics Lung Neoplasms - metabolism
Melanoma - diagnosis Melanoma - genetics Melanoma - metabolism
Meningioma - diagnosis Meningioma - genetics Meningioma - metabolism
Mesothelioma - diagnosis Mesothelioma - genetics Mesothelioma - metabolism
Mutation -
Neoplasms - diagnosis Neoplasms - genetics Neoplasms - metabolism
Nevus, Epithelioid and Spindle Cell - diagnosis Nevus, Epithelioid and Spindle Cell - genetics Nevus, Epithelioid and Spindle Cell - metabolism
Paraganglioma - diagnosis Paraganglioma - genetics Paraganglioma - metabolism
Skin Neoplasms - diagnosis Skin Neoplasms - genetics Skin Neoplasms - metabolism
Tumor Suppressor Proteins - genetics
Ubiquitin Thiolesterase - genetics
Uveal Neoplasms - diagnosis Uveal Neoplasms - genetics Uveal Neoplasms - metabolism

Find related publications in this database (Keywords)
3p21 loss syndrome
atypical Spitz tumour
BAP1
diagnosis
familial cancer
germline mutation
inherited tumour susceptibility
melanoma
pathology
skin
uveal melanoma
© Meduni Graz Impressum